1月28日 - ** 医疗技术公司Glaukos GKOS.N股价盘前上涨4%至122.94美元
** 该公司称 (link) 美国FDA现在允许医生再次使用其 "iDose TR "植入物，这种植入物能稳定释放青光眼药物以降低眼压。
** 青光眼是一种损害视神经的疾病，通常是由于眼内压力过高造成的；该植入物为那些难以每天滴眼药水的患者提供了一种选择。
** 该公司称，更新后的标签允许医生移除原来的植入物，然后放置新的植入物，试验表明这种方法在一年内是安全的。
** GKOS 称，患有某些角膜问题或感染的患者不建议使用该设备
** 2025 年股价下跌约 25%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.